Switch theme
Sign up to access all valuation multiples
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
2006
59
LTM Revenue $41.3M
LTM EBITDA -$66.1M
$369M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zevra Therapeutics has a last 12-month revenue of $41.3M and a last 12-month EBITDA of -$66.1M.
In the most recent fiscal year, Zevra Therapeutics achieved revenue of $23.6M and an EBITDA of -$76.4M.
Zevra Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zevra Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $27.5M | $23.6M | XXX | XXX | XXX |
| Gross Profit | $10.1M | $24.5M | XXX | XXX | XXX |
| Gross Margin | 37% | 104% | XXX | XXX | XXX |
| EBITDA | -$43.5M | -$76.4M | XXX | XXX | XXX |
| EBITDA Margin | -159% | -324% | XXX | XXX | XXX |
| Net Profit | -$41.5M | -$46.0M | XXX | XXX | XXX |
| Net Margin | -151% | -195% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zevra Therapeutics's stock price is $7.
Zevra Therapeutics has current market cap of $378M, and EV of $369M.
See Zevra Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $369M | $378M | XXX | XXX | XXX | XXX | $-1.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zevra Therapeutics has market cap of $378M and EV of $369M.
Zevra Therapeutics's trades at 8.9x LTM EV/Revenue multiple, and -5.6x LTM EBITDA.
Analysts estimate Zevra Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zevra Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $369M | XXX | XXX | XXX |
| EV/Revenue | 15.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.8x | XXX | XXX | XXX |
| P/E | -3.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZevra Therapeutics's NTM/LTM revenue growth is 159%
Zevra Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.7M for the same period.
Over next 12 months, Zevra Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zevra Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zevra Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -324% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 75% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -164% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 178% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 437% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zevra Therapeutics acquired XXX companies to date.
Last acquisition by Zevra Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Zevra Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zevra Therapeutics founded? | Zevra Therapeutics was founded in 2006. |
| Where is Zevra Therapeutics headquartered? | Zevra Therapeutics is headquartered in United States of America. |
| How many employees does Zevra Therapeutics have? | As of today, Zevra Therapeutics has 59 employees. |
| Who is the CEO of Zevra Therapeutics? | Zevra Therapeutics's CEO is Mr. Neil F. McFarlane, M.S.. |
| Is Zevra Therapeutics publicy listed? | Yes, Zevra Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Zevra Therapeutics? | Zevra Therapeutics trades under ZVRA ticker. |
| When did Zevra Therapeutics go public? | Zevra Therapeutics went public in 2015. |
| Who are competitors of Zevra Therapeutics? | Similar companies to Zevra Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zevra Therapeutics? | Zevra Therapeutics's current market cap is $378M |
| What is the current revenue of Zevra Therapeutics? | Zevra Therapeutics's last 12-month revenue is $41.3M. |
| What is the current EBITDA of Zevra Therapeutics? | Zevra Therapeutics's last 12-month EBITDA is -$66.1M. |
| What is the current EV/Revenue multiple of Zevra Therapeutics? | Current revenue multiple of Zevra Therapeutics is 8.9x. |
| What is the current EV/EBITDA multiple of Zevra Therapeutics? | Current EBITDA multiple of Zevra Therapeutics is -5.6x. |
| What is the current revenue growth of Zevra Therapeutics? | Zevra Therapeutics revenue growth between 2023 and 2024 was -14%. |
| Is Zevra Therapeutics profitable? | Yes, Zevra Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
